Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study

Ankrah, Daniel; Lartey, Margaret; Mantel‐Teeuwisse, Aukje K.; Leufkens, Hubert G. M.

doi:10.1186/s12879-017-2752-7

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of dyslipidemia is reportedly higher in people living with HIV due to the effect of ART in Ghana [9][10][11]. The severity of dyslipidemia and the typical pattern of the lipid profile differ between and within the classes of antiretroviral (ARV) agents [12].…”

Section: Introductionmentioning

confidence: 99%

Association of single nucleotide polymorphisms with dyslipidemia in antiretroviral exposed HIV patients in a Ghanaian population: A case-control study

et al. 2020

View full text Add to dashboard Cite

Dyslipidemia is a potential complication of long-term usage of antiretroviral therapy (ART) and also known to be associated with genetic factors. The host genetic variants associated with dyslipidemia in HIV patients on ART in Ghana have not been fully explored. The study constituted a total of 289 HIV-infected patients on stable ART for at least a year. Fasting blood was collected into EDTA tube for lipids measurement. Lipid profiles were used to define dyslipidemia based on the NCEP-ATP III criteria. HIV-infected subjects were categorized into two groups; those with dyslipidemia (cases) (n = 90; 31.1%) and without dyslipidemia (controls)(n = 199; 68.9%). Four candidate single nucleotide polymorphism (SNP) genes (ABCA1-rs2066714, LDLR-rs6511720, APOA5-rs662799 and DSCAML1-rs10892151) were determined. Genotyping was performed on isolated genomic DNA of study participants using PCR followed by a multiplex ligation detection reaction (LDR). The percentage of the population who had the rare homozygote alleles for rs6511720 (T/T), rs2066714 (G/G), rs10892151 (T/T) and rs662799 (G/G) among case subjects were 5.5%, 14.4%, 6.6% and 10.0% whiles 2.0% 9.1%, 6.5% and 4.0% were observed among control subjects. There were statistically significant differences in the genotypic prevalence of APOA5 (p = 0.0357) and LDLR polymorphisms (p = 0.0387) between case and control subjects. Compared to the AA genotype of the APOA5 polymorphisms, individuals with the rare homozygote genotype [aOR = 2.38, 95%CI(1.06-6.54), p = 0.004] were significantly associated with an increased likelihood of developing dyslipidemia after controlling for age, gender, treatment duration, CD4 counts and BMI. Moreover, individuals with the rare homozygous genotype of ABCA1 (G/G) [aOR = 10.7(1.3-88.7), p = 0.0280] and LDLR (rs6511720) G>T [aOR = 61.2(7.6-493.4), p<0.0001) were more likely to have high levels of total cholesterol levels. Our data accentuate the presence of SNPs in four candidate genes

show abstract

Section: Introductionmentioning

confidence: 99%

Association of single nucleotide polymorphisms with dyslipidemia in antiretroviral exposed HIV patients in a Ghanaian population: A case-control study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The prevalence of dyslipidemia is reportedly higher in people living with HIV due to the effect of ART in Ghana [12-14]. The severity of dyslipidemia and the typical pattern of the lipid profile differ between and within the classes of antiretroviral (ARV) agents [15].…”

Section: Introductionmentioning

confidence: 99%

Association of Single Nucleotide Polymorphisms with Dyslipidemia in Antiretroviral Exposed HIV Patients in a Ghanaian population

Obirikorang

Acheampong

Quaye

et al. 2019

Preprint

View full text Add to dashboard Cite

Dyslipidemia is a potential complication of long-term usage of antiretroviral therapy (ART) and also known to be associated with genetic factors. The host genetic variants associated with dyslipidemia in HIV patients on ART in Ghana have not been fully explored. The study constituted a total of 289 HIV-infected patients on stable ART for at least a year and 85 aged matched apparently healthy control subjects with no history of HIV and dyslipidemia. Fasting blood was collected into EDTA tube for lipids measurements. Lipid profiles were determined as a measure of dyslipidemia. HIV-infected patients were categorized into two groups; those with dyslipidemia(HIV-Dys+) (n=90; 31.1%) and without dyslipidemia (n=199; 68.9%) based on the NCEP-ATP III criteria. Four candidate single nucleotide polymorphisms (SNPs) genes (ABCA1-rs2066714, LDLR-rs6511720, APOA5-rs662799 and DSCAML1-rs10892151) were determined. Genotyping was performed on isolated genomic DNA of study participants using PCR followed by a multiplex Ligation Detection Reaction (LDR). The percentage of the population who had the rare homozygote alleles for rs6511720 (T/T), rs2066714 (G/G), and rs10892151 (T/T) and rs662799 (G/G) among HIV+Dys+ subjects were 5.5%, 14.4%, 6.6% and 10.0%; 2.0% 9.1%, 6.5% and 4.0% among HIV+Dys- subjects while 3.5%, 4.7%, 4.7% and 2.4% were observed in HIV-Dys- subjects. Statistically significant difference in genotypic prevalence of APOA5 polymorphisms was observed among different groups (p=0.0196). Compared to the AA genotype of the APOA5 polymorphisms, individuals with the rare homozygote genotype [aOR =4.01, 95%CI(1.57-22.39), p=0.004] were significantly more likely to develop dyslipidemia after controlling for age, gender, treatment duration and CD4 counts among the HIV+Dys+ subjects. There was also a significant associated between GG genotype of ABCA1 and dyslipidemia [aOR =3.29, 95% (1.08 -12.43); p=0.042] . Individuals with the rare homozygote variant (GG) of APOA5 (rs662799) were significantly associated with increased likelihood of developing dyslipidemia [OR =2.24, 95% CI (1.20 -6.83); p=0.0370] holding other variables constant in the HIV+Dys- subjects. Our data accentuate the presence of SNPs in four candidate genes and its association with dyslipidemia among HIV patients exposed to ART in the Ghanaian population especially variants in APOA5-rs662799 ABCA1-rs2066714 respectively. These findings provide baseline information that necessitates a pre-symptomatic strategy for monitoring dyslipidemia in ART-treated HIV patients. There is a need for longitudinal studies to validate a comprehensive number of SNPs and its association with dyslipidemia.

show abstract

“…Se ha reportado que las causas de cambios en los esquemas y de su abandono suelen estar relacionadas con efectos secundarios, fatiga por parte del paciente hacia la ingesta del tratamiento, o factores relacionados al estilo de vida de los pacientes [11]; sin embargo, otro tipo de factores pueden también modificar las decisiones sobre cambios terapéuticos en diferentes áreas, como en África donde un cambio de política tuvo un impacto significativo que se asoció con el tipo de tratamiento, el año de tratamiento, el sexo y la etapa de la enfermedad [12].…”

Section: Introductionunclassified

Complejidad de la transición de los esquemas antirretrovirales en un programa de atención de VIH en Bogotá durante el periodo de 2015-2017

Arévalo-Mora¹,

Moscoso²,

Acosta³

et al. 2019

Rev. Colomb. Cienc. Quím. Farm.

View full text Add to dashboard Cite

Cuando se decide cambiar una terapia antirretroviral se puede llegar a limitar futuras opciones‚ y es allí donde las conductas del personal tratante deben ser las más acertadas. Se realizó un estudio transversal-descriptivo‚ revisando las principales causas de cambios de esquema en los pacientes VIH de la IPS CEPAIN de Bogotá (Colombia) durante el periodo 2015-2017. Los cambios de tratamiento se estimaron en 8,1%; 8,8% y 5,8% durante los 3 años, el principal motivo de cambio fueron las reacciones adversas con 53,1%; 46%, y 49,6% respectivamente‚ seguidos de simplificación con 17,5; 25,1 y 26,5% y fracaso terapéutico en 19,8; 20,9 y 14,8% para cada año. Durante el primer año de tratamiento existió la necesidad de cambiar los esquemas en 12,9; 18,5, y 7,6% de los pacientes que iniciaron tratamiento en esos respectivos años. Las decisiones en los cambios de tratamiento antirretroviral involucran la introducción de nuevos antirretrovirales, la necesidad de reducir el número de tabletas o medicamentos, distintos perfiles de eficacia, tolerancia, efectos secundarios, toxicidad, barrera genética e interacciones. Otros factores a tener en cuenta son: el costo creciente de los medicamentos antirretrovirales, la dinámica en la transición y aplicación de los nuevos esquemas para garantizar un enfoque clínico, y económico sustentable.

show abstract

Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study

Cited by 3 publications

References 20 publications

Association of single nucleotide polymorphisms with dyslipidemia in antiretroviral exposed HIV patients in a Ghanaian population: A case-control study

Association of single nucleotide polymorphisms with dyslipidemia in antiretroviral exposed HIV patients in a Ghanaian population: A case-control study

Association of Single Nucleotide Polymorphisms with Dyslipidemia in Antiretroviral Exposed HIV Patients in a Ghanaian population

Complejidad de la transición de los esquemas antirretrovirales en un programa de atención de VIH en Bogotá durante el periodo de 2015-2017

Contact Info

Product

Resources

About